SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Eli Lilly
LLY 1,076+0.4%9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bull-like who wrote (198)5/1/1998 3:14:00 PM
From: D.J.Smyth  Read Replies (1) of 642
 
The analyst spoke with physicians: How would physicians know if they are going to prescribe Evista if they do not know the test results as yet? Granted some physicians were involved in the study, but exactly which physicians were involved is highly guarded information. I can imagine that a physician might say "I'll prescribe if the test results are good, but if the results are equal to tamoxifin treatment, well..." Lilly has stated that initial test results from Evista show that it does not carry the side affects of tamoxifin and is equally effective.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News